CA-125 Test: Tumor Marker Levels & Cancer Monitoring
CA-125, or cancer antigen 125, is a protein that is often elevated in ovarian cancer but can also be elevated in other cancers and benign conditions. While primarily used for monitoring ovarian cancer treatment response and detecting recurrence, CA-125 levels alone cannot diagnose cancer. A comprehensive approach integrating CA-125 results with imaging studies, clinical symptoms, and expert medical judgment is essential for accurate assessment.
Interpreting CA-125 Test Results Online
Interpreting your CA-125 test results online helps you understand this tumor marker measurement in the context of ovarian cancer screening or monitoring. CA-125 is measured in units per milliliter (U/mL), with levels above 35 U/mL typically considered elevated. Online resources explain what different levels may indicate, though professional medical interpretation is crucial since elevated CA-125 does not automatically mean cancer. Serial measurements and trends over time often provide more useful information than a single result.
What is CA-125 and Why it's Important
CA-125 is a glycoprotein produced by epithelial ovarian cancer cells and various other cell types. While strongly associated with ovarian cancer, CA-125 is not cancer-specific and can be elevated in many benign conditions. Its primary clinical value is monitoring ovarian cancer patients during and after treatment to detect early recurrence, which allows for timely intervention. Rising CA-125 levels after treatment can prompt earlier detection of recurrent disease compared to clinical symptoms alone.
Normal CA-125 Levels and Cancer Risk
Normal CA-125 levels are generally below 35 U/mL in non-pregnant women. However, elevated levels do not diagnose cancer—they indicate need for further investigation. Approximately 80% of women with advanced ovarian cancer have elevated CA-125, but only 50% of early-stage cases show elevation. CA-125 is more valuable as a monitoring tool during cancer treatment than for initial screening. The combination of CA-125 with imaging (ultrasound, CT) and clinical assessment provides better cancer detection than CA-125 alone.
Elevated CA-125: Causes and Clinical Significance
Elevated CA-125 can result from numerous benign causes including menstruation, pregnancy, endometriosis, adenomyosis, uterine fibroids, pelvic inflammatory disease, and liver disease. Non-ovarian cancers including breast, lung, pancreatic, and gastrointestinal cancers can also elevate CA-125. Even benign conditions like pancreatitis or diverticulitis may increase levels. Therefore, CA-125 elevation requires comprehensive clinical evaluation including imaging and gynecologic examination to determine the underlying cause.
CA-125 Monitoring: Screening and Follow-up Strategies
CA-125 monitoring is most valuable for ovarian cancer patients undergoing treatment and during follow-up surveillance for recurrence. Serial measurements showing a declining trend during chemotherapy usually indicate good treatment response. In contrast, rising CA-125 levels during or after treatment may indicate treatment failure or early recurrence. Regular CA-125 measurement every 3-6 months during follow-up allows detection of recurrent cancer often months before symptoms develop, enabling earlier intervention and potentially better outcomes.
How CA-125 is measured and what to expect during the test
A CA-125 test is a routine venous blood draw. A health care professional takes a sample from a vein in your arm using a small needle, and a small amount of blood is collected into a tube or vial. The entire procedure usually takes less than five minutes. You may feel a brief sting when the needle goes in or out, but most people tolerate it without difficulty.
No special preparation is required. You do not need to fast, change medications, or follow a special diet beforehand. If your provider asks you to follow specific instructions, that guidance is usually tied to other tests being drawn in the same appointment rather than to CA-125 itself.
Risks and side effects
The risks of a CA-125 blood test are minimal. You may notice slight pain or bruising at the puncture site, but these symptoms typically resolve quickly. Serious complications are uncommon.
How the sample is analyzed
The lab measures the amount of cancer antigen 125 (CA-125) — a protein, sometimes called a glycoprotein antigen or ovarian cancer antigen — in your blood. CA-125 is a type of biomarker, meaning it is a substance in your blood that may signal a condition or disease. Reproductive-system tissues such as the ovaries and fallopian tubes can release CA-125 when those organs are inflamed, including in response to normal events like menstruation. Results come back in units per milliliter (U/mL) and are usually reviewed together with imaging, symptoms, and your medical history rather than read in isolation.
How to interpret your results
A CA-125 number is not a yes/no cancer answer. Your provider reads it alongside the rest of your clinical picture — symptoms, imaging, prior values, and your risk profile — to decide what to do next. The same number can mean very different things depending on why the test was ordered.
Interpretation by clinical context
| Clinical context | What the result suggests | Typical next step |
|---|---|---|
| Treatment monitoring during ovarian cancer therapy | A downward trend across several tests usually means treatment is working | Continue current treatment plan |
| Post-treatment surveillance | Rising levels over time may signal that ovarian cancer is coming back | Imaging and clinical reassessment |
| Suspicious pelvic lump on imaging | High CA-125 raises concern but cannot confirm cancer on its own | Further tests; only a biopsy can diagnose ovarian cancer |
| High-risk individual without symptoms | Elevated CA-125 prompts more testing rather than a diagnosis | Imaging, gynecologic evaluation, possible referral |
| Average-risk person without symptoms | Test result is hard to act on because false positives and false negatives are common | CA-125 generally not indicated |
Why trends matter more than single numbers
A single CA-125 value rarely tells the full story. During active ovarian cancer treatment, providers compare several tests in a row to judge whether numbers are going down, holding steady, or rising. After treatment, surveillance is the same idea in reverse — providers watch for an upward drift that may mark recurrence before symptoms appear. This is why serial measurements are central to how CA-125 is used.
A normal CA-125 result is reassuring but not absolute. Levels can be low in the early stages of ovarian cancer, and some people with confirmed disease never make high CA-125 at all. That limitation is one reason CA-125 is not used as a stand-alone screening test in the general population.
Who should and shouldn’t get CA-125 testing
CA-125 testing is targeted, not universal. It is most useful when there is a specific clinical reason to order it. For people without symptoms or risk factors, the test is generally not helpful and can create more confusion than clarity.
People for whom CA-125 may be appropriate
- People currently being treated for ovarian cancer, to monitor whether therapy is working
- People who have finished ovarian cancer treatment, to watch for recurrence
- People with a suspicious pelvic lump seen on imaging, as one piece of a broader workup
- BRCA1 or BRCA2 carriers, where inherited gene changes raise ovarian cancer risk
- People with Lynch syndrome (hereditary non-polyposis colorectal cancer), which raises risk for several cancers including ovarian
- People with a mother or sister who had ovarian cancer, or two or more other relatives with ovarian cancer
- People with family members who have had breast or colorectal cancer
- People who have personally had breast, uterine, or colorectal cancer
- People with a biological family member who had ovarian cancer
People for whom CA-125 is generally not recommended
CA-125 is not useful as a routine screen in people who have no symptoms and no elevated risk. Many benign conditions can push the number up — including menstruation, pregnancy, endometriosis, pelvic inflammatory disease, uterine fibroids, and liver disease — so a high result in a low-risk person is more likely to lead to anxiety and follow-up imaging than to a cancer diagnosis. Related tumor markers such as CEA and CA 19-9 follow the same principle: they shine when monitoring a known cancer and falter when used as broad screens.
False positives, false negatives, and the limits of CA-125
CA-125 can be normal in people who have ovarian cancer, and it can be elevated in people who do not. Both kinds of mistakes — false negatives and false positives — are why a CA-125 test is not considered an effective screening tool for ovarian cancer on its own.
Why a normal result doesn’t rule out cancer
CA-125 levels can be low in the early stages of ovarian cancer, and some people with the disease never produce high CA-125. A reassuring number is meaningful but not definitive, especially if you have new pelvic symptoms or a suspicious imaging finding.
Why screening healthy people doesn’t work
A comprehensive review of CA-125 in ovarian cancer concluded that screening average-risk, asymptomatic people with CA-125 is not recommended by any professional society. The reasoning has two parts. First, the type II tumors that drive most ovarian cancer deaths are usually diagnosed in advanced stages and are rarely caught in stages I or II — so focusing CA-125 screening on early detection has not improved survival. Second, the traditional 35 U/mL cutoff produces too many false positives in the general population, which leads to unnecessary imaging and procedures.
Researchers continue to explore whether different cutoffs — typically higher than 35 U/mL — and point-of-care testing in primary care might improve performance in defined populations, but those approaches are still being studied and are not standard clinical practice.
CA-125 combined with imaging and other tests
A CA-125 result almost never travels alone. Providers combine the number with imaging, physical examination, and sometimes additional blood markers to build a fuller picture. The combination is what makes the workup useful; the marker by itself is too noisy to act on.
Where each piece fits
- Physical and pelvic examination to check for masses, tenderness, or other findings that may explain symptoms.
- Imaging such as ultrasound or other studies to look for a pelvic lump or characterize one already seen.
- CA-125 to add a biochemical data point when a lump or high-risk situation has already raised concern.
- Biopsy, which is the only test that can actually diagnose ovarian cancer — imaging and CA-125 can suggest the diagnosis but never confirm it.
HE4 as a companion marker
For epithelial ovarian cancer — the most common type — providers sometimes order a second tumor marker called HE4 alongside CA-125. Some studies suggest that measuring both markers together gives more accurate information about whether treatment is working and whether the cancer is coming back than CA-125 alone. HE4 is not a replacement for CA-125 and is not used in every case; it is one of several tools a provider may bring in depending on the situation.
CA-125 is also used in the diagnosis, treatment, and monitoring of cancers of the fallopian tubes and the peritoneum, the membrane lining the abdominal cavity. The same principles apply: pair the number with imaging and clinical evaluation rather than reading it in isolation.
Frequently asked questions
Can a CA-125 test diagnose cancer on its own?
No. A CA-125 test cannot diagnose cancer by itself. Elevated levels can come from many non-cancer conditions, and normal levels do not rule out ovarian cancer. Only a biopsy can actually confirm an ovarian cancer diagnosis.
Why might my CA-125 be high if I don’t have cancer?
Many benign conditions can elevate CA-125. These include menstruation, pregnancy, endometriosis, pelvic inflammatory disease, uterine fibroids, and liver disease. The ovaries and fallopian tubes can release CA-125 simply because they are inflamed.
Does a normal CA-125 rule out ovarian cancer?
No. CA-125 levels can be low in the early stages of ovarian cancer, and some people with the disease never produce high CA-125. A normal result is reassuring but not definitive, especially if you have new symptoms or a suspicious pelvic lump.
Is CA-125 used to screen for breast or endometrial cancer?
No. CA-125 is used in the diagnosis, treatment, and monitoring of ovarian cancer, as well as cancers of the fallopian tubes and peritoneum. It is not a screening test for breast or endometrial cancer, though a personal history of breast or uterine cancer is one factor that raises ovarian cancer risk.
What does CA-125 mean if I have an ovarian cyst?
If a suspicious lump shows up on imaging, your provider may order CA-125 alongside other tests to help figure out whether the lump could be ovarian cancer. A high CA-125 raises concern, but it does not confirm cancer — and a normal CA-125 does not fully rule it out.
Why isn’t CA-125 used to screen healthy people?
Screening average-risk, asymptomatic people with CA-125 is not recommended by any professional society. False positives and false negatives are common, which makes the test a poor fit for population-level screening. CA-125 is most useful for people who already have a known reason to test.
How is CA-125 used during chemotherapy?
During ovarian cancer treatment, providers run several CA-125 tests over time. A downward trend across those tests usually means treatment is working, while levels that go up or stay flat may mean it is not.
What is HE4 and why is it sometimes ordered with CA-125?
HE4 is a second tumor marker sometimes used together with CA-125 in epithelial ovarian cancer — the most common type. Some studies suggest the two markers together provide more accurate information about treatment response and recurrence than CA-125 alone.
When to talk to your doctor
CA-125 is a clinical tool, not a self-screen. Bring it up with a provider — rather than ordering it on your own — in situations like these:
- You have a mother or sister who had ovarian cancer, or two or more other relatives with ovarian cancer
- You have family members with breast or colorectal cancer, which can raise your own ovarian cancer risk
- You carry BRCA1 or BRCA2 gene changes, or have been told you have Lynch syndrome
- You have personally had breast, uterine, or colorectal cancer, which can raise the risk of developing ovarian cancer
- You have a pelvic lump or mass found on imaging or examination, and your provider wants to characterize it further
- You are currently being treated for ovarian cancer and your provider has not yet discussed how CA-125 will be tracked
- You have finished treatment for ovarian cancer and want to understand the schedule for monitoring recurrence
- Your CA-125 result has come back elevated and you want help understanding what the next step looks like for your specific situation
A provider who knows your history can interpret a number in context, weigh the benign explanations, and decide whether further testing — imaging, additional blood work, or referral to a specialist — actually changes management.
References
- MedlinePlus (U.S. National Library of Medicine, NIH)
- Cleveland Clinic
- PubMed (U.S. National Library of Medicine, NIH)